OSCR
Oscar Health, Inc.
OSCR has the edge over PIII overall, supported by stronger fundamentals.
PIII
P3 Health Partners Inc.
PIII's outlook is improving, though it still trails on the overall score.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
PIII Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Stable | |
| Under pressure | |
| Weak |
PIII's revenue is currently healthy, and its profitability is stable, but its cash flow and balance sheet are under pressure.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
PIII PE Valuation
PIII has no meaningful PE right now: it lost money over the past year.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for OSCR, with profitability improving.
PIII Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| -- |
Analysts expect PIII's losses to shrink, with revenue growing.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over PIII on earnings quality, reporting a profit while its opponent remains loss making.
PIII Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$33.06 | +$17.95 |
| Q1 2026 | -$38.66 | +$13.62 |
| Q4 2025 | -$45.26 | +$8.74 |
| Q3 2025 | -$45.18 | -$4.18 |
| Q2 2025 | -$51.01 | -$19.51 |
| Q1 2025 | -$52.28 | -$23.78 |
| Q4 2024 | -$54.00 | -$22.50 |
| Q3 2024 | -$41.00 | +$93.00 |
PIII is still losing money, but far less than before: $33.06 per share over the past year, against $134.00 at its worst in late 2023.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over PIII on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
PIII Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $396.3M | +15% |
| Q2 2026 | $386.4M | +8.6% |
| Q1 2026 | $386.4M | +3.5% |
| Q4 2025 | $384.8M | +3.8% |
| Q3 2025 | $345.3M | -4.7% |
| Q2 2025 | $355.8M | -6.2% |
| Q1 2025 | $373.2M | -3.9% |
| Q4 2024 | $370.7M | +6.9% |
PIII's revenue has grown year over year for four quarters in a row: $396M last quarter, up 15% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 5.8% | +19 points |
| Q2 2026 | 11% | +20 points |
| Q1 2026 | 2.1% | +12 points |
| Q4 2025 | -40% | -2.6 points |
| Q3 2025 | -13% | +17 points |
| Q2 2025 | -9.6% | -1.3 points |
| Q1 2025 | -10% | +1.1 points |
| Q4 2024 | -37% | -19 points |
PIII has the edge over OSCR on profitability, with a higher operating margin.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with PIII at down 6.5%.
PIII Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$61.9M | -$45.3M |
| Q1 2026 | -$27.5M | +$6M |
| Q4 2025 | -$25.7M | +$31.5M |
| Q2 2025 | -$16.6M | -$6.4M |
| Q1 2025 | -$33.5M | -$13.4M |
| Q4 2024 | -$57.2M | -$41.6M |
| Q3 2024 | -$22.6M | -$14.6M |
| Q2 2024 | -$10.2M | +$19.8M |
PIII has burned cash in almost every quarter: −$116M over the past year, against −$130M the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has the edge over PIII on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
PIII Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +97% | +3.3M shares |
| 1 year | +103% | +3.4M shares |
| 3 years | +6% | +373K shares |
PIII has 7M diluted shares, up 103% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | $180,000 |
| Q1 2020 | — |
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has the edge over PIII on leverage, with a lower net debt burden relative to earnings.
PIII Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 28.6x | High |
PIII's net debt is more than 20 years of its operating earnings (EBITDA).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
PIII Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.3 | Oversold |
| Stochastic | 2.8 | Oversold |
PIII's weekly RSI is 29 (oversold) and its Stochastic is 3 (oversold).
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
PIII PE vs Healthcare Sector
PIII has no meaningful PE right now: it lost money over the past year.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over PIII on trend strength, trading above more of its moving averages.
PIII Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.68 | 41% below |
| 20 week MA | $7.81 | 65% below |
| 50 week MA | $6.16 | 55% below |
| 100 week MA | $7.25 | 62% below |
| 200 week MA | $34.7 | 92% below |
PIII is in a downtrend: it's below all five of its weekly moving averages, and 92% below its 200-week average.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over PIII on returns for 2026, with the stronger performance.
PIII Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $488.5 | $363.0 | -26% |
| 2022 | $363.0 | $101.5 | -72% |
| 2023 | $101.5 | $70.5 | -31% |
| 2024 | $70.5 | $10.0 | -86% |
| 2025 | $10.0 | $3.57 | -64% |
| 2026 YTD | $3.57 | $2.75 | -23% |
PIII has finished every year since 2021 lower, and it's down 23% so far in 2026.